Supplementation is simply a way to provide the body with more of what it already creates
Furthermore, the application of a multifunctional agonist targeting the GLP-1, GIP, and delta-opioid (DOR) receptorssuch as DPDPErepresents a novel therapeutic strategy for obesity, particularly given that DOR activation has been shown to independently improve glucose homeostasis (Olianas et al., 2011) and insulin sensitivity (Meulebrouck et al., 2024), as well as regulating emotional aspects of eating behavior (Wassum et al., 2009
Furthermore, stem cell therapy, a burgeoning modality for ED treatment, has seen certain experimental findings transition to clinical applications
The role of phospholipid oxidation products in inflammatory and autoimmune diseases: Evidence from animal models and in humans
They make clinical sense when managing documented metabolic adaptation, addressing specific complaints of profound fatigue on GLP-1s, or when gastrointestinal side effects prevent the use of standard therapies
Food and Drug Administration (FDA) approval of oforglipron as a diabetes treatment as soon as possible. The company is already pursuing approval of orforglipron for obesity, and expects a decision from the FDA this spring
